Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Disease Modification Conundrum in Parkinson’s Disease: Failures and Hopes
Zoltán Mari, Tiago Mestre
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Machine Learning and Digital Biomarkers Can Detect Early Stages of Neurodegenerative Diseases
Artur Chudzik, Albert Śledzianowski, Andrzej W. Przybyszewski
Sensors (2024) Vol. 24, Iss. 5, pp. 1572-1572
Open Access | Times Cited: 29
Parkinson’s Disease and Photobiomodulation: Potential for Treatment
Brian Bicknell, Ann Liebert, Geoffrey Herkes
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 112-112
Open Access | Times Cited: 12
Targeting Neuroinflammation by Pharmacologic Downregulation of Inflammatory Pathways Is Neuroprotective in Protein Misfolding Disorders
Sydney Risen, Sean W. Boland, Sadhana Sharma, et al.
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 7, pp. 1533-1547
Closed Access | Times Cited: 12
Opportunities and Pitfalls of REM Sleep Behavior Disorder and Olfactory Dysfunction as Early Markers in Parkinson’s Disease
Beatrice Orso, Sarah Brosse, Johannes Frasnelli, et al.
Journal of Parkinson s Disease (2024) Vol. 14, Iss. s2, pp. S275-S285
Open Access | Times Cited: 6
Cognitive Impairment in Parkinson’s Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches
Yıldız Değirmenci, Efthalia Angelopoulou, Vasiliki Georgakopoulou, et al.
Medicina (2023) Vol. 59, Iss. 10, pp. 1756-1756
Open Access | Times Cited: 16
Alleviating Stress in Parkinson’s Disease: Symptomatic Treatment, Disease Modification, or Both?
Franziska Goltz, Anouk van der Heide, Rick C. Helmich
Journal of Parkinson s Disease (2024) Vol. 14, Iss. s1, pp. S147-S158
Open Access | Times Cited: 5
A Comparative Study of Machine Learning and Deep Learning Models for Automatic Parkinson’s Disease Detection from Electroencephalogram Signals
Swagota Bera, Zong Woo Geem, Young Im Cho, et al.
Diagnostics (2025) Vol. 15, Iss. 6, pp. 773-773
Open Access
Early Alterations in De Novo Parkinson’s Disease Revealed by Diffusion Tensor Imaging: Preliminary Study
Francesca Di Giuliano, Noemi Pucci, Maria Lina Serio, et al.
Diagnostics (2025) Vol. 15, Iss. 7, pp. 841-841
Open Access
From past to future: Digital approaches to success of clinical drug trials for Parkinson's disease
Cen Cong, Madison Milne‐Ives, Ananya Ananthakrishnan, et al.
Journal of Parkinson s Disease (2025)
Open Access
Gut-brain axis: gut dysbiosis and psychiatric disorders in Alzheimer’s and Parkinson’s disease
Charlotte R. Denman, Sang Myun Park, Junghyun Jo
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 9
Identification of Prodromal Parkinson Disease
Richard Rees, Alastair Noyce, Anette Schrag
Neurology (2024) Vol. 102, Iss. 11
Open Access | Times Cited: 3
Selecting the Best Animal Model of Parkinson’s Disease for Your Research Purpose: Insight from in vivo PET Imaging Studies
Caroline Cristiano Real, Karina Henrique Binda, Majken Borup Thomsen, et al.
Current Neuropharmacology (2023) Vol. 21, Iss. 5, pp. 1241-1272
Open Access | Times Cited: 8
On the Role of Iron in Idiopathic Parkinson’s Disease
Sandro Huenchuguala, Juan Segura‐Aguilar
Biomedicines (2023) Vol. 11, Iss. 11, pp. 3094-3094
Open Access | Times Cited: 7
Classification of Parkinson’s Disease Using Machine Learning with MoCA Response Dynamics
Artur Chudzik, Andrzej W. Przybyszewski
Applied Sciences (2024) Vol. 14, Iss. 7, pp. 2979-2979
Open Access | Times Cited: 2
Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson’s disease
Angela Minnella, Kevin P. McCusker, Akiko Amagata, et al.
PLoS ONE (2024) Vol. 19, Iss. 9, pp. e0309893-e0309893
Open Access | Times Cited: 2
Solid lipid nanoparticles for efficient delivery of capsaicin-rich extract: Potential neuroprotective effects in Parkinson’s disease
Lisa Marinelli, Marilisa Pia Dimmito, Ivana Cacciatore, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 91, pp. 105097-105097
Closed Access | Times Cited: 6
Feasibility of Simon 2-Stage Futility Trials in Early Parkinson Disease
Marcus Koch, Lorraine V. Kalia, Justyna R. Sarna, et al.
Neurology (2024) Vol. 104, Iss. 1
Closed Access | Times Cited: 1
Targeting neuroinflammation by pharmacologic down-regulation of inflammatory pathways is neuroprotective in protein misfolding disorders
Sydney Risen, Sean W. Boland, Sadhana Sharma, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 7
Therapeutic Effect of Human Adipocyte-derived Stem Cell-derived Exosomes on a Transgenic Mouse Model of Parkinson’s Disease
Lung Chan, Wayne Hsu, Kai‐Yun Chen, et al.
In Vivo (2023) Vol. 37, Iss. 5, pp. 2028-2038
Open Access | Times Cited: 2
Editorial: Biomarkers of non-motor symptoms in Parkinson's disease and parkinsonisms
Massimo Filippi, Roberta Balestrino, Federica Agosta
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 2
The adenosine A2A receptor is a therapeutic target in neurological, heart and oncogenic diseases
Rafael Franco, Alejandro Lillo, Gemma Navarro, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 9, pp. 791-800
Closed Access | Times Cited: 3
Applying technologies to unmet clinical needs in movement disorders
Zoltán Mari
Elsevier eBooks (2024), pp. 39-48
Closed Access
An Ethnographic Study of Patient Life Experience in Early-Stage Parkinson’s Disease in the United States and Germany
Todd Carmody, Rebekah Park, Elisabeth E. Bennett, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 4, pp. 1219-1235
Open Access
Templating of Monomeric Alpha-Synuclein Induces Inflammation and SNpc Dopamine Neuron Death in a Genetic Mouse Model of Synucleinopathy
Matthew Byrne, Peyman Petramfar, Richard J. Smeyne
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Early α-synuclein/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease
Marcello Serra, Gaia Faustini, Viviana Brembati, et al.
Experimental Neurology (2024) Vol. 383, pp. 115040-115040
Closed Access
Page 1 - Next Page

Scroll to top